Can Magic Mushrooms Help Me Quit Smoking?
The clinical trial results are in, and they are more surprising than almost anyone expected.
The nicotine patch has had a good run. Decades of shelf space at every pharmacy in America. Billions in sales. A reliable, if modest, success rate.
Then a randomized clinical trial published in JAMA Network Open in early 2026 found that one dose of psilocybin produced six times the quit rate of the nicotine patch at the six-month mark.
One dose. Six times.
That number deserves to sit for a second.
Part I: The Smoking Study That Changed the Conversation
The trial, led by Matthew Johnson at Johns Hopkins University School of Medicine, enrolled 82 adult smokers. Not casual smokers. People averaging 16 cigarettes a day, with a median of six previous failed quit attempts. People who had tried before and failed, repeatedly.
Both groups went through 13 weeks of cognitive behavioral therapy for smoking cessation. Same starting line. Then, at the designated quit date, one group received a single high dose of psilocybin. The other started a standard nicotine patch regimen.
At the six-month mark, 40.5% of the psilocybin group had remained abstinent, verified biochemically. In the nicotine patch group, that number was 10%.
“I was surprised by the sheer magnitude of the effect,” Johnson told NPR. It was the first randomized comparison between a psychedelic intervention and an established smoking cessation treatment.
This built on an earlier open-label pilot study, also from Johns Hopkins, which found that 80% of participants were biologically verified as smoke-free at six months. At the 30-month follow-up, a significant portion remained abstinent. Those results were striking enough that the NIH awarded Johns Hopkins its first federal grant in over 50 years to directly study the therapeutic effects of a classic psychedelic.
Part II: Why It Works, and Why It’s Not What You’d Expect
Here’s what makes psilocybin such an unexpected smoking cessation tool: it doesn’t touch the nicotinic receptors that cigarettes hijack.
It doesn’t suppress cravings the way varenicline does. It doesn’t replace one delivery mechanism with another the way nicotine replacement therapy does. It works somewhere else entirely — on serotonin receptors, on neural network flexibility, on how people relate to their own habits and sense of self.
Participants in the psilocybin group were encouraged beforehand to use the session to examine what smoking actually meant to them. During the eight to nine hour session, lying with eyeshades and listening to music, many reported profound shifts in how they saw themselves as smokers. Not just wanting to quit, but no longer identifying as someone who smokes.
Addiction psychiatrist Dr. Brian Barnett of the Cleveland Clinic described the drug as harnessing neuroplastic and learning effects rather than simply replacing or blocking the substance being misused. A fundamentally different approach from anything currently on the market.
It also connects to what we know about how psilocybin changes the brain more broadly, loosening rigid patterns of thinking and behavior that entrench habits, including the habit of reaching for a cigarette every time a specific emotion or context appears.
Part III: Smoking Isn’t the Only Target
The smoking results are the most dramatic, but psilocybin is showing up across the addiction research landscape.
A phase 2 randomized clinical trial published in The Lancet’s eClinicalMedicine in 2025 found that a single dose of psilocybin combined with brief psychotherapy significantly reduced relapse rates in patients with alcohol use disorder. The trial was conducted in Switzerland and built on earlier pilot data showing substantial reductions in heavy drinking days after psilocybin-assisted therapy.
A separate JAMA Psychiatry trial found meaningful reductions in the percentage of heavy drinking days compared to an active placebo, with the effect persisting well beyond the dosing session itself.
A systematic review published in ScienceDirect in 2025 examined 16 published studies across different substance use disorders and found preliminary evidence supporting psilocybin’s efficacy and safety for both alcohol use disorder and tobacco use disorder, particularly when combined with psychotherapy. Research into cocaine and opioid use disorders is earlier stage but actively underway, with over 100 active clinical trials currently investigating psilocybin across a range of conditions.
Part IV: Why Addiction Is So Hard to Treat
Nicotine and alcohol don’t just create physical dependence. They wire themselves into identity, routine, emotion regulation, and social behavior. The cigarette after coffee. The drink at the end of a hard day. These aren’t just habits, they’re coping structures built around stress, trauma, or deeply held beliefs about who you are and what you need.
Standard pharmacological treatments address the physical side. They reduce cravings, block receptors, manage withdrawal. What they largely can’t do is address the psychological architecture underneath.
Psilocybin appears to work at that deeper level. By temporarily loosening the brain’s most rigid patterns, it opens a window where those underlying structures can be examined and sometimes dismantled. The mystical or deeply meaningful experience many participants report isn’t a side effect. In the research, it’s consistently identified as the mechanism. The participants who reported the most profound sessions were the ones most likely to still be smoke-free two and a half years later.
It also connects to what the research shows about psilocybin and identity change. People don’t just feel better after a psilocybin session. They sometimes feel differently about who they are and what they want. That’s a harder thing to manufacture, and a more durable one.
Part V: What This Doesn’t Mean Yet
Every study showing significant outcomes has been conducted with professional facilitation, careful preparation, and therapeutic support before and after the session. The psilocybin isn’t doing this alone. It’s doing it inside a structured container of care and intention.
Sample sizes in most trials are still relatively small. Larger, more diverse trials are needed before psilocybin-assisted therapy becomes a standard clinical option. FDA approval for psilocybin treatment remains pending in the United States, meaning access through legitimate medical channels is still limited.
Set and setting matter here as much as anywhere. The conditions under which the experience happens shape what it produces. The same molecule that helped chronic smokers quit in a Johns Hopkins clinical setting would not necessarily produce the same results in an unguided context without preparation or integration.
The research is pointing clearly in one direction. The infrastructure for delivering this at scale doesn’t fully exist yet.
The Bigger Picture
It’s been 20 years since a new medication for smoking cessation entered the market. Megan Piper, who directs the University of Wisconsin Center for Tobacco Research and Intervention, said it plainly to NPR: “We need something novel, and this is definitely a novel approach.”
Not a patch. Not a pill that blocks receptors. A single session that appears to change how people see themselves, at a level other interventions can’t reach.
If you’re curious about starting a more intentional relationship with mushrooms, browse our range at SmilesHigh.Club. And if microdosing is on your radar, our Magically Microdosed Gummies are a thoughtful place to begin.
Trip safely, know your source, and respect the experience. Visit SmilesHigh.Club for more.
